The expansion is the result of a collaborative deal announced earlier this month with New York-based OSI Pharmaceuticals. Genentech also will continue working with Massachusetts-based Alkermes Inc. to develop Nutropin, the human growth hormone that has been on the market since 1997.
Although the project has not been awarded yet, company officials expect to begin the expansion this summer. Once finished, Genentech will have nearly 600,000 sf of space at the site, making it the largest research facility of its kind in the world.
The company's building spree has spilled over into other projects, such as its facility at 700 Forbes Blvd., where construction is under way for a two-story, 60,000 sf building scheduled to open in March. Hathaway Dinwiddie Construction is currently overseeing the project.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
